All articles by Swagath Bandhakavi
Swagath Bandhakavi
SystImmune announces FDA clearance of IND application for BL-M17D1 in advanced solid tumours
The clearance of this IND application marks an important milestone for SystImmune as the company continues to advance its pipeline of novel therapeutic candidates into clinical development
Avid Bioservices to go private in $1.1bn deal with GHO and Ampersand
Upon completion of the transaction, the Nasdaq-listed CDMO’s shares will cease to be publicly traded, though the company will continue to operate under the same name and brand
EU approves Dupixent for treating eosinophilic esophagitis in young children
Developed jointly by Sanofi and Regeneron Dupixent is administered through a subcutaneous injection
Sonnet BioTherapeutics issues US patent for Variant IL-18 in novel immunotherapeutic candidates
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)
Dyno Therapeutics, Roche sign $1.05bn deal for neurological gene therapy development
The partnership will utilise Dyno Therapeutics’ platform technology, allowing Roche to broaden its development of next-generation AAV gene therapies across several targets
ImmunityBio begins dosing in Phase 1 trial of CAR-NK therapy for relapsed NHL
The open-label study in South Africa aims to enrol up to 10 participants, with full enrolment expected by Q1 2025 and initial data anticipated in H2 2025
Cancer Research UK, KisoJi Biotechnology to advance the first naked antibody against TROP2 into clinic
KisoJi will supply the antibody for the clinical trial and work with CDD to complete the preclinical package
GSK and Boston University team up for pulmonary fibrosis research
The partnership seeks to enhance the understanding of pulmonary fibrosis and discover new drug targets by utilising lung cells developed by CReM
OmniaBio opens new commercial manufacturing facility in Canada, bringing life-saving cell and gene therapies to patients
The site will add state-of-the-art CGT capacity and employ artificial intelligence and automation to achieve critical product supply efficiencies for North American and global biotherapy clients
Merck’s clesrovimab significantly cuts RSV hospitalisations in MK-1654-004 trial
The findings showed an over 84% reduction in RSV-related hospitalisations and more than 90% in hospitalisations linked to RSV-related lower respiratory infections during a five-month observation period